Stay updated with breaking news from Gary Dubin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Takeda Pharmaceuticals' dengue vaccine assumes significance since the first vaccine ever licensed for dengue, developed by French drugmaker Sanofi Pasteur, met with failure as it only helped people who had been previously infected with the virus.
Every year dengue claims several lives in India and across the globe. Recently, a Japanese pharma company has tied up with Indian vaccines maker Biological E to roll out doses against this mosquito borne infection. - Dengue Vaccine: Japan's Pharma Ties Up With India to Manufacture Over 50 Million Doses of QDENGA - 4 Points to Know
Biological E will scale up its production capacity to potentially reach 50 million doses annually
Takeda's dengue vaccine is currently available for children and adults in countries like Indonesia, Thailand, Argentina and Brazil.
Biological E will scale up its production capacity to potentially reach 50 million doses annually, accelerating Takeda's efforts to manufacture 100 million doses annually within the decade